Journal article
Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer
Abstract
Background:Despite palliative benefits and PSA responses, the objective clinical impact of daily oral prednisone (P) for metastatic castration-resistant prostate cancer (mCRPC) is unknown. We performed a pooled analysis of control arms of randomized trials that either did or did not administer single-agent P to evaluate its impact on overall survival (OS) and toxicities.Methods:Individual patient data from control arms of randomized trials of …
Authors
Sonpavde G; Pond GR; Templeton AJ; Kwon ED; De Bono JS
Journal
Prostate Cancer and Prostatic Diseases, Vol. 20, No. 1, pp. 67–71
Publisher
Springer Nature
Publication Date
3 2017
DOI
10.1038/pcan.2016.44
ISSN
1365-7852